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Abstract 
Traditional Chinese medicine (TCM) is a theoretical based system and is completely different from 
western medicine and states that numerous diseases, especially chronic diseases, are cured or 
relieved. “Zheng” (syndrome) is a summarization of the pathological changes which take place 
during the different stages of the development of a disease, including its location, cause and nature as 
well as the state of both Xie-qi (pathogenic factors) and Zheng-qi (healthy energy). Compared to a 
single symptom, syndrome can demonstrate the nature of a disease more extensively, completely and 
correctly. However, it is difficult to compare “Zheng” to the western medicine theory, which is based 
on scientific evidence for the diagnosis and treatment of a specific disease. Estrogen deﬁciency is a 
major pathogenetic factor in bone loss after menopause and oophorectomy with the subsequent risk 
of developing osteoporosis. According to TCM theory, the kidney stores essence and this can 
transform into bone marrow to nourish the bones, strenghthen the skeleton by promoting growth and 
repair. The kidney deﬁciency can decrease the estrogen level adjusted by the gonadal axis, causing 
osteoporosis. Traditional Chinese medicines tonifying the kidney can significantly enhance the level 
of estrogen to alleviate osteoporosis. In combination with other evidence, we further deduce that the 
syndrome as defined within TCM has a similar pathological mechanism to that defined by western 
medicine. If TCM theory is to be understood and accepted, and further fused with the western 
medicine theory, the micro pathological basis of TCM syndrome must be investigated extensively, 
which will lead to bridging the two theories together. The fusion of TCM with western medicine will 
pay more attention to analyzing the common nature and difference of disease and syndrome. This 
paper reviews the way forward for new translational advances. 
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Introduction 
Traditional Chinese medicine (TCM) believes that the human body is composed of viscera, 
meridians, five sensory organs, nine orifices, four limbs and skeletal parts. These different tissues 
and organs are united into five functional systems according to their interdependency in structure, 
physiology and pathology, this includes the heart, liver, spleen, lung and the kidney system. On one 
hand, human beings depend on nature to provide them with various necessities, such as sunlight, air 
and water whilst on the other hand, various changes taking place in nature can affect human bodies 
directly or indirectly and cause corresponding physiological or pathological responses. 
Bian-Zheng-Lun-Zhi (syndrome differentiation and treatment) is a basic principle of TCM and 
is based on analyzing, inducing, synthesizing, judging and summarizing the clinical data of 
symptoms and signs collected with four diagnostic methods (namely inspection, listening and 
smelling, inquiry, taking pulse and palpation) into a certain syndrome, and then a therapeutic method 
is chosen according to the results of syndrome differentiation. “Zheng” (syndrome) is a 
summarization of the pathological changes at a certain stage duringthe course of development of a 
disease, including the location, cause and nature of the disease as well as the state of Xie (pathogenic 
factors) and Zheng (healthy qi). Compared to a single symptom, syndrome can demonstrate the 
nature of a disease more extensively, completely and correctly. 
Clinically, syndrome-differentiation (Bian-Zheng) and disease-differentiation (Bian-Bing) are 
intrinsically interrelated although significantly different from each other. It is generally thought that 
disease includes the whole pathological course while syndrome is just a summarization of the 
pathological changes at a certain development stage of a disease. A syndrome (Zheng) may appear in 
different diseases, while different diseases may reveal the same syndrome (Zheng) in their 
development which is the basis of Bian-Zheng-Lun-Zhi. The essence of Bian-Zheng-Lun-Zhi is that 
the same syndrome is treated with the same therapy while the different syndromes are treated with 
the different methods. Therefore in TCM, understanding and treatment of disease mainly focuses on 
differentiating syndromes and analyzing the common nature or difference of syndromes in the course 
of differentiating disease.  
The organ kidney is located in the waist, which is the house of the kidney according to 
Huang-Di-Nei-Jing (a famous monograph on traditional Chinese medicine theory). The kidney stores 
essence (jing), which is transformed into qi to leading to the production of blood. The kidney is also 
the source of genuine yin (zhen-yin) and genuine yang (zhen-yang). Therefore the kidney is closely 
related with the essence, qi, blood, yin and yang. Since the kidney-essence (shen-jing) comes from 
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parents and is the primary substance for constituting human body and conceiving new life, TCM 
regards the kidney as “the prenatal basis of life”. The kidney has several important physiological 
functions, one of which is the regulation of the bone. It means that the development and function of 
the bone depends on the kidney-essence, which contains the kidney yin and kidney yang. The kidney 
stores essence and the essence can transform into bone marrow to nourish the bone, promote the 
growth and repair of the skeleton and strengthen the skeleton. If kidney-essence is deficient, it will 
affect the production of bone marrow, leading to flaccidity of the skeleton and hypoevolutism in 
infants as well as brittleness of the bone and susceptibility to fracture in the aged [1]. These 
symptoms are regarded as indicators of kidney deficiency syndrome in TCM, which is the most 
important cause of osteoporosis. 
Osteoporosis is a common skeletal disorder characterized by low bone mass and 
micro-architectural deterioration of bone tissue with increased fracture susceptibility [2]. The strong 
and dense bone results from a balance between bone breakdown (resorption) and bone formation. A 
disruption in the interplay between bone-building osteoblasts and bone-degrading osteoclasts can 
lead to osteoporosis [3]. One-second women and one-fifth men over the age of 50 years will suffer a 
fracture due to osteoporosis during their lifetime and demographic changes in the next few decades 
will result in at least a doubling in the number of these fractures[4]. Despite the increasing public 
awareness of this disorder, the control rate of osteoporosis remains unsatisfactory, and a substantial 
proportion of people under treatment do not achieve the effective control recommended by current 
guidelines. Suboptimal bone growth in childhood and adolescence is as important as later in life bone 
loss in the development of osteoporosis [5]. In 2001, the NIH Consensus Development Panel on 
Osteoporosis Prevention, Diagnosis, and Therapy suggested that both men and women experience an 
age-related decline in BMD starting in midlife. Women experience more rapid bone loss in years 
following menopause, which places them at earlier risk of fractures Whilst in men, hypogonadism is 
also an important risk factor [5]. Estrogen deficiency is a major pathogenetic factor of bone loss after 
menopause and oophorectomy with thesubsequent risk of developing osteoporosis. Endogenous and 
exogenous estrogens play an important rolein skeletal function at molecular, cellular and tissue levels 
via genomic and nongenomic actions [6]. After binding to ER-α and ER-β in bone cells, they can 
facilitate osteoblast formation by regulation of cytokines, such as IL-6 and IL-11 and they also 
increase osteoclast apoptosis [7]. In TCM, “osteoporosis” does not exist but in view of pathogenesis 
and clinical manifestations, it is largely associated with “atrophic debility of the bone” [8]. 
In the 1950s, Shen Ziyin, an academician, discovered that the value of urinary 17-hydroxy is 
generallydown-regulatedin patientswith kidney-yang deficiency and following this extensive 
research was undertaken to verifythe reliability of this result. Subsequently, Shen first put forward 
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that TCM syndrome possesses material foundation [9]. The advance aging in 
hypothalamic-pituitary-gonadal axis function is considered to be one of the essences of kidney-yang 
deficiency[10]. Consolidating the renal essence can ameliorate the symptoms in elderly male, and 
this method is relatively specificic for the gonads [11]. Chen also recorded that there is an 
interconnection between gonad and kidney deficiency in TCM [12]. 
Estrogen deficiency is a major pathogenetic factor for the development of osteoporosis, while 
kidney deficiency has an intimate connection with the gonads. Accordingly, one has to address the 
questions if there is any essential association between kidney deficiency and osteoporosis 
development? What is the essential association? In recent years, the interest in the further 
development of herbal or botanical drug products derived from traditional preparations has increased 
significantly. A large number of new drugs from TCM are used in clinical and folk medicine and 
their effectiveness based on the extensive human use has been confirmed. Therefore, searching for 
the appropriate fusion between TCM syndrome and modern medicine is a promising channel to find 
new treatment methods and to guide the development and clinic use of medicines that stem from 
TCM theory and modern medicine technique. Successful implementation of this principle into the 
development programs foranti-osteoporosis drugs will substantially contribute to the clinically 
successful applications of anti-osteoporosis drugs in the future. In this article, we describe the current 
regulatory environment of osteoporosis treatment development in TCM, and summarize our 
regulatory experiences and delineated the scientific and regulatory issues involved. We hope that an 
introduction to the relationship between kidney deficiency and osteoporosis will stimulate more 
research leading to the development of new treatments based on TCM.  
Osteoporosis and estrogen deﬁciency 
The use of gonadal steroids (estrogens and progestogens) is a logical intervention in the prevention 
of osteoporosis [13] since these are important determinants of peak and lifetime bone mass in men, 
women, and children [5]. A great deal of evidence indicates that gonadal steroids, particularly 
estrogens and androgenic progestogens, induce small increments in skeletal mass which are not 
followed by a progressive decrease in bone density. Thus, dose-appropriate estrogens prevent bone 
loss, irrespective of whether these are given in the immediate menopausal period or when bone loss 
is established [13]. In 1996s, JAMA reported postmenopausal women assigned to placebo 
demonstrated decreased BMD at the spine and hip, whereas women assigned to estrogen therapy 
increased BMD during a 36-month period. These findings demonstrate that estrogen replacement 
therapy increases BMD at clinically important sites [14]. Also, the use of estrogen in these 
postmenopausal women signiﬁcantly decreased the risk of osteoporosis andsubsequent fracture, as 
reported in a large double-blind randomized clinical trial, the Women’s Health Initiative (WHI) in 
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2002 [15]. Hormone replacement therapy (HRT) is an established approach for osteoporosis 
treatment and prevention. Observational studies have indicated a significant reduction in the 
occurrence of hip fracture in cohorts of women who maintain HRT therapy. 
Kidney deficiency and estrogen deficiency 
The research by Shen Ziyin has proved that TCM Zheng (syndrome) has a material foundation, and 
there is substantial evidence supporting a crucial role of hypothalamus in deficiency of the kidney 
[16]. The age-related changes elicited by gonadal axis are very similar to symptoms induced by 
deficiency of the kidney. The hypothalamic-pituitary-gonadal axis displays premature aging to a 
certain degree ie one of the essences of kidney deficiencyis areproductive endocrine dysfunction. 
Meanwhile, it has been confirmed that reinforcing the kidney can improve gonadal axis function by 
way of “proved syndrome by medicines” (mentioned in Table 2). These investigations indicate that 
within the context of TCM, “kidney” is linked to the function of reproductive endocrine in modern 
medicine as the sexual hormones levels also decrease in the female with kidney deficiency [17]. On 
the other hand, most animal experiments have substantiated that kidney-tonifying Chinese medicines 
can improve the function of hypothalamic-pituitary-gonadal axis in the animal models of kidney 
deficiency. These findings are consistent with the results of modern medical research for osteoporosis, 
indicating that estrogen deficiency is probably a joint pathological basis of kidney deficiency and 
osteoporosis. 
Kidney deficiency and osteoporosis 
The TCM theory believes that the kidney plays a central role in human health,and is regarded as “the 
prenatal base of life”. Governing the bones is one of the most important functions of the kidney in 
TCM and according to its theory the essence (jing) stored in the kidney can transform into bone 
marrow to nourish the bones, strengthen the skeleton  by promoting its growth and repair. The 
deﬁciency of kidney-essence can affect the production of bonemarrow, leading to ﬂaccidity of 
skeleton [18]. As a corollary, kidney deficiency would be a permissive requirement for sustaining 
chronic reductions of bone. In addition, the association of kidney deficiency with osteoporosis risk is 
cited as supporting a key contribution of kidney deficiency to the pathogenesis of osteoporosis. 
Moreover, estrogen agents are a cornerstone of current anti-osteoporosis therapy, which have an 
anti-resorptive effect on bone by acting as an inhibitor of osteoclast function and by stimulation of 
osteoclast apoptosis [19]. It is suggested that estrogen deﬁciency up-regulates osteoclastogenesis 
through increasing the production of pro-osteoclastogenic cytokines TNF-α and RANKL. A previous 
investigation also demonstrated that menopausal women, who have an increase in the number of 
osteoclastogenesis, suffer from post-menopausal osteoporosismore easily than those matched for the 
same period [20]. Meanwhile, the Women’s Health Initiative (WHI) study presented the first 
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evidence ina large randomized controlled trial that HRT or oestrogen alone (ORT) reduces the risk of 
all osteoporosis-related fractures, even in patients at low risk of fracture [19]. These studies suggest 
that kidney deficiency and osteoporosis have a common pathological basis, that is, disorder of 
gonadal axis and/ (or) reduction of estrogen levels. 
Diagnosis 
Until the first fracture occurs, osteoporosis is a silent disease without any symptoms or increased 
morbidity. Once the first fracture occurs, the risk of subsequent fractures will double with every new 
fracture, with a resultant increase in morbidity and mortality [19]. The main symptom of 
osteoporosisis pain and particular complications may arise from fractures of the spine and hip. The 
treatment of osteoporosis, therefore, aims to reduce the fracture rate by means of increasing bone 
strength, a parameter driven by bone mineral density (BMD) and bone quality. BMD, frequently used 
as a proxy measure, accounts for approximately 70% of bone strength (a surrogate endpoint inmany 
clinical trials for osteoporosis), which is generally measuredby dual energy X-ray absorptiometry 
(DXA). It has been regarded as a good predictor for fracture risk [21], nevertheless, there are 
currently no accurate methods of measurement for overall bone strength. The World Health 
Organization (WHO) operationally defines osteoporosis as bone density 2.5 SDs below the mean for 
young white adult women. It is not clear how this diagnostic criterion can be applied to men and 
children, or across ethnic groups [5]. The monitoring of treatment by serial measurement of BMD 
has serious pitfalls such as individual variations in precision of operators and devices. 
Kidney deficiency can cause osteoporosis and based on the TCM theory, the kidney governs the 
bones, including its development and function and as such the essence of kidney is yin and yang. 
Clinically, kidney-yin deficiency or kidney-yang deficiency can lead to osteoporosis. Er-Zhi-Wan 
(EZW), a famous traditional Chinese medicine formulation, has been developed as a restorative 
preparation for hundreds of years, which is composed of two herbs viz. the aerial part of Eclipta 
prostrate L. and the fruit of Ligustrumlucidum Ait. EZW is widely used to prevent and treat various 
kidney diseases due to its efficacy for nourishing the kidney yin andstrengthening tendon and bones 
[18]. You-Gui-Wan (YGW), another famous traditional Chinese medicine formulation, possesses the 
actions of warming and enriching kidney-yang, and replenishing essence and marrow. This recipe 
can be used for the treatment of kidney-yang deficiency syndrome and is applicable to nephritic 
syndrome and senile osteoporosis, etc [22]. 
Diagnostically, the criteria in accordance with the TCM theory is:  
a. Deficiency of the kidney-yin 
Vertigo, soreness of the waist and knees, seminal emission or spermatorrhea, night sweat, 
spontaneous persoiration, dry mouth and tongue, reddened tongue with little fur, thread pulse.  
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b. Deficiency of the kidney-yang 
Qi deficiency and mental fatigue from senility or protracted disease, aversion to cold and cold 
limbs, soreness and weakness of the waist and knees, pale tongue with whitish fur, deep and slow 
pulse. 
For example, the following symptoms occur in the experimental model of rats with kidney-yang 
deficiency induced by hydrocortisone. On the first five day, the rats gradually display vertical hair, 
body curled up, convergence, half blind eyes, more urination, etc. From 11 to 14 days, the 
symptomsof kidney-yangdeficiency are more obvious, including loss of weight, dry hair and 
relaxation, cold limb, dulleyes, unresponsive, decreased spontaneous activity, squinting or closed 
eyes, leaden feet, low and weak cry, reductions in diet and water intake, increased urination and urine 
volume, etc. It is very similar to TCM characteristic symptoms of kidney-yang deficiency [23]. 
Accordingly, You-Gui-Wan (YGW) reverses these symptoms and evidently protects rats from 
kidney-yang deficiency. It coincides with “principle-method-recipe-medicines” of the syndrome of 
kidney-yang deficiency [23,24]. Although the animal models do not recapitulate all of the features of 
human osteoporosis elicited by kidney deficiency, they have nevertheless provided useful insights 
that have proved relevant to human disorders based on the TCM theory. 
Current treatment and the unmet need  
Current pharmacological treatments of osteoporosis (hormone therapy, selective estrogenreceptor 
modulators, bisphosphonates, strontium ranelate, denosumab, etc.) are largely palliative (rather than 
curative) and some may result in nonspecific immunosuppression. This may be associated with a 
range of complications including breast secretions, gynecomastia, vasodilation, abdominal pain, 
headache, disturbances of consciousness, etc. For these reasons, there is renewed enthusiasm for 
strategies aiming to find more effective drugs and (or) treatment guideline. Due to osteoporosis being 
a chronic condition, it takes longer to show treatment effects of drugs, thus requiring longer and 
larger studies. 
Therapeutic strategies should be designed to include the combined use of drugs with distinct but 
convergent mechanisms that can amplify treatment efficacies and diminish adverse effects. Although 
prevalent in postmenopausal women, osteoporosis also occurs in all populations and at all ages and 
has significant physical, psychosocial, and financial consequences. Clinical risk factors have an 
important but poorly effective role in determining who should receive BMD measurement, in 
assessing fracture risk, and in determining who should be treated. Both concept of holism and 
syndrome differentiation and treatment are the two basic characteristics of TCM in understanding 
human physiology and pathology as well as diagnosis, treatment and prevention of disease. The 
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application of TCM prescription went through the process from experience to theory. At first people 
chose prescriptions and drugs in the light of syndrome only but with the increasing prescriptions and 
long-term clinical practices, they gradually summarized some regularity of the prescriptions, and 
then the therapeutic theory came into being. The different syndromes have different principles of 
treatment. For instance, osteoporosis induced by deficiency of kidney-yang should be treated by 
warming and activating kidney-yang and replenishing kidney essence. Osteoporosis induced by 
deficiency of kidney-yin should be treated by nourishing yin and invigorating the kidney. Assessment 
of bone mass, identification of fracture risk, and determination of who should be treated are the 
optimal goals when evaluating patients for osteoporosis.  
Postmenopause estrogen replacement therapy is an established treatment for the prevention of 
osteoporosis in healthy women [25]. The etiology of estrogen deficiency cannot be determined in the 
vast majority of individuals with ‘essential’ osteoporosis in the TCM theory. Thus, it has proved 
difficult to develop precise profiles of individual patients for the purposes of identifying optimal 
therapies and predicting prognosis. Consequently, choices of anti-osteoporosis therapy are typically 
empirical and are based on broad epidemiological categories such as age, race and the presence of 
coexisting disorders such as spleen or liver deficiency. Accordingly, developing a more precise 
understanding of the molecular pathogenesis of osteoporosis remains a pressing priority for both 
TCM and modern medicine researchers in the field. 
Although it is possible to initiate expanded clinical trials on some well-characterized and widely 
used botanical preparations without the support of nonclinical toxicity data, additional animal studies 
may be needed for final marketing approval. Although these animal models (deficiency of kidney-yin 
and deficiency of kidney-yang) do not fully recapitulate all of the features of human kidney 
deficiency, they have nevertheless provided useful insights that have proved relevant to human 
disorders. In this review, we have cited and discussed the work using these models as well as studies 
in humans and animals to illustrate recent progress in the treatment of osteoporosis. 
New drugs in development 
Before the early 1990s, fewer than ten botanical INDs had been submitted to the FDA. As the FDA 
initiated its plan to draft botanical guidelines in the mid-1990s, interest in developing botanical drugs 
escalated [26]. Unlike most small-molecule drugs that comprise a single chemical compound, 
Veregen, an extract of green tea leaves, contains a mixture of known and possibly active compounds. 
It is the first new botanical prescription drug approved since the publication of the FDA’s industry 
guidelines for botanical drug products in June 2004 [26]. It indicates a growing interest over 
therapeutic needed in rigorous clinical evaluation of botanical drugs, with a focus on indications 
where there is a clear medical need for new treatments. However, the efficacies of traditional Chinese 
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medicines have been verified by prior human experience and availabilityas dietary supplements 
before thousands of years when approved as drugs. Therefore, nonclinical toxicity studies to support 
the initial human trials were waived for most botanical applications. The common serious 
deficiencies resulting in clinical hold include previous human experiences and/or existing animal 
toxicity data, which are inadequate to support the safety of the proposed clinical trial. However, for 
many botanical preparations, extensive human experience can provide some degree of comfort in 
their safety, but the past human experiencehas rarely been documented rigorously. In this regard, 
these are either withdrawn by the sponsors or remain on clinical hold, and interpretation of the 
experience has been a problem in designing clinical trials. 
Conclusions and future perspectives 
Concept of holism (Zheng-Ti-Guan) and syndrome differentiation and treatment 
(Bian-Zheng-Lun-Zhi) are the two most basic characteristics of TCM in understanding human 
physiology and pathology as well as diagnosis, treatment and prevention of disease. Holistic 
conception guides syndrome analysis of all aspects and conditions of disease, which refers to 
different constitutions of disease. Treatment according to syndrome differentiation improves local 
pathological changes through regulating holistic function, which is the practical application of 
holistic conception. Researchers’ inability to distinguish the causes of osteoporosis in individual 
people is a major obstacle for developing more personalized and effective approaches to clinical 
management. For example, one disease may demonstrate different syndromes which should be 
treated by different therapies due to differences in constitution, onset of disease, geographic 
conditions, or stage of development. Therefore, treatment decisions should be individualized and a 
general guideline should consider individual difference in pharmacological therapy. The decision, of 
when to begin and what type of treatment to use, should be made on the basis of the need to reduce 
fracture risk. Furthermore the agent used (estrogen, SERM, bisphosphonates) may vary over a 
woman’s life time. Based on the theoretical study and clinical practice made by the previous 
generations and with the adoption of modern scientific theory and technology, TCM will fuse with 
modern scientific theory and technology reasonably and effectively. 
Osteoporosis generally does not present symptoms until clinically significant bone fracture 
occurs. Despite reflection of bone turnover, the changes in bone mineral density (BMD) and in 
biochemical markers of bone metabolism do not measure bone quality [27]. The numerous 
investigations indicate that estrogen deficiency is a joint pathological basis of both kidney deficiency 
and osteoporosis. Meanwhile estrogen significantly decreases the risk of osteoporosis and subsequent 
fracture arising in postmenopausal women. According to evidence presented, we deduce that TCM 
syndrome (Zheng) and modern disease probably have a common material basis (Figure 1). TCM 
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could be fused with modern scientific theory and technology; however, some unmet points still exist 
in present research. 
TCM theory believes that set prescriptions can be modified according to the actual requirements. 
The efficacies of Chinese traditional medicines are summarized through long-term clinical 
observations and repetitive practice, gradually developing into a theory. However, in alternative 
medicine, the definitions for diagnoses, symptoms and treatment-related adverse events are often 
vague and difficult to understand or do not correlate with Western medical terminology. Furthermore, 
the variability and complexity of natural chemical constituents will make it extremely difficult in 
most cases to establish a definition for ‘equivalence’ between botanical drugs and to prove that two 
‘similar’ products are pharmacologically identical or therapeutically interchangeable, as many 
botanical products and traditional medicines are traditionally used on the basis of the theory and 
practice of alternative medicine. It will be a technical challenge to define botanical new drugs 
consistent with both TCM theory and modern medicine. The combination of clinical information 
collection and BMD testing with syndrome differentiation and treatment (Bian-Zheng-Lun-Zhi) may 
be available for determination who has a risk for development of fractures, osteoporosis or other 
diseases. Prospectively, we may be able to improve on this risk assessment by using advanced 
imaging techniques and methods based on TCM theory and modern medicine for assessing human 
disease. This will depend on indications, the kinds of study (placebo control or comparison of 
batches) and other factors. Although not all of the above approaches will be necessary for every case, 
the combination of some of these will be usually effective. 
Syndrome is established generally by analysis, induction, synthesis, judgment and 
summarization of the clinical data of symptoms and signs collected by the four diagnostic methods 
(namely inspection, listening and smelling, inquiry, taking pulse and palpation). However, as 
diagnostic criteria largely depend on doctors’ clinical experience, the syndrome is affected for its 
reliability and accuracy. In recent years, the research for syndrome material foundation relates to the 
ultrastructure, physiology and biochemistry. Nevertheless, each TCM syndrome contains not only 
several physical and chemical indicators, but also the network link between the multi-level indices. 
The corresponding level inconsistency between physical and chemical indicators and syndrome 
determines that a single indicator or simple superposition of indicators cannot explain all aspects of 
TCM syndrome. Based on the concept of holism, the essence research of syndrome does not look for 
specific substance from body, but should investigate the body physiological material, pathological 
basis and their spatial and temporal distribution. 
In physiology, viscera perform various functions by cooperation with each other. In pathology, 
morbid changes in any part of the body will affect other viscera and tissues or even the whole body. 
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Similarly, general pathological changes of the body will affect the function of the local viscera. 
Kidney-yin deficiency and kidney-yang deficiency can be distinguished in theory and clinic, but their 
research findings are a bit vague on the significance of gonadal axis connotation which is described 
as changing the structure and/or its function. However, is there any difference in the degree or link of 
gonadal axis changes? What is the difference? These questions have not been addressed yet. 
Presumably the main reason is that the other syndromes disturbed the syndromes investigated. It may 
draw a positive conclusion that the characteristics of syndrome are selected to establish the 
multi-syndrome comparative study. 
In order to conduct an in-depth study of syndrome, animal experiments must be conducted and 
comply with the theory and clinical practice of TCM. The experiment would be meaningless if an 
appropriate animal model fails. As syndrome is a summarization of the pathological changes of a 
disease at a certain stage in its course of development, it can be affected by variations of the season, 
geographical conditions, weather, and other operation practices. Batch-to-batch inconsistency is also 
a common problem. In different periods, different syndromes can transform and reinforce each other 
in the same individual, which are relative clinical concepts. The TCM theory puts a great emphasis 
on the dialectical relationship between yin and yang, especially as the concept of holism. For 
example, no matter the kidney or spleen deficiency, qi or blood deficiency, they are ultimately 
interrelated and reinforced with each other as a holism. In this regard, a standard principles outline of 
animal experiments should be formulated by following scientific test and good collection practice for 
starting materials of clinical syndrome origin. 
However, traditional Chinese medicine and modern medicine are two different academic 
disciplines, and have different ways of thinking. Modern medicine lays emphasis on the structure and 
part and usually uses unilateral antagonist therapy. However TCM focuses on function and the whole, 
and generally gives multifaceted regulation therapy. In fact, TCM is complementary with modern 
medicine by commensurate treatment and (or) proportional amelioration of disease. Meanwhile, as 
the costs and time involved with drug discovery show no immediate sign of decreasing, despite the 
advent of many new technologies, most savings will be made by parallelizing processes. For 
example, instead of waiting for a protease and (or) gene to be validated as an osteoporosis-relevant 
target, Chinese herbal medicines whose effectiveness have been substantiated by human experience 
are applied. A vast amount of information, including clinic experience, substrate specificity, assay 
development and initial screening for the interacting compounds, can be gathered beforehand and 
potentially extrapolated to other, related osteoporosis-relevant material basis based on the fusion of 
traditional Chinese medicine with western medicine. Going forward, application of these different 
treatment theories to the issue of the modern medicine disease has great promise. 
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Syndrome (Zheng) and disease are intrinsically interrelated on one hand, but are also different 
from each other. Disease includes the whole pathological course, while syndrome is just the 
summarization of certain stage in the course of the disease. For this reason one disease may display 
different syndromes, while different diseases may demonstrate the same syndrome in their course of 
development. TCM places emphasis on analyzing the common nature and difference of syndrome in 
the course of disease development. 
In conclusion, kidney deficiency and osteoporosis have a joint pathological basis. Based on the 
existing evidence, we further deduce that TCM syndrome possibly has a joint pathological basis with 
modern disease. If TCM theory is to be accepted and further fused with the western medicine theory, 
the micro pathological basis of TCM syndrome must be investigated extensively, thus bridging these 
two theoretical systems. The fusion of TCM with modern medicine will pay more attention to 
analyzing the common nature and differences of the disease and syndrome. 
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Figure 1 TCM syndrome (Zheng) and modern disease probably has a joint pathological basis 
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Table 1 Traditional medicines for the treatment of osteoporosis induced by estrogen deficiency 
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Botanical name Family Medicinal 
part 
Pharmacological effect Model  Reference 
Achyranthes bidentata 
Blume 
Amaranthaceae Root Decrease of bone loss in ovariectomized 
rats by inhibiting osteoclast formation 
Ovariectomized rats [28] 
 
Cuminum cyminum L. Apiaceae Fruit Prevention of bone loss caused by 
ovariectomy 
Ovariectomized rats [29] 
Ferula hermonis Boiss Apiaceae Root Prevention of bone loss caused by severe 
estrogen deﬁciency 
Ovariectomized rats [30] 
Acantho panax 
senticosus Harms 
Araliaceae Stem Decrease of bone loss in 
postmenopausal women 
Postmenopausal 
women 
[31] 
Lepidium meyenii Maca Brassicaceae Root Improvement of the bone mass in 
ovariectomized rats 
Ovariectomized rats [32] 
Sambucus williamsii 
Hance 
Caprifoliaceae Stem and 
ramulus 
Suppression of the ovariectomy induced 
increase in bone turnover, inhibition of 
bone resorption, and stimulation of bone 
formation 
Ovariectomized rats [33] 
Silybum marianun  (L.) 
Gaertn 
Compositae Seed Prevention of bone loss caused by 
ovariectomy with mild proliferative 
eﬀects in uterus 
Ovariectomized rats [34] 
Cibotiumbarometz (L.) 
J.Sm. 
Dicksoniaceae Rhizome Prevention of bone loss induced by 
ovariectomy 
Ovariectomized rats [35] 
Dipsacus asperoides C. Y. 
Cheng et T. M. Ai 
Dipsacaceae Root Inhibition of bone loss induced by 
ovariectomy 
Ovariectomized rats [36,37] 
Vaccinium 
angustifolium  Ait. and V. 
Ericaceae Fruit Prevention of bone loss in ovarian 
hormone deﬁciency 
Ovariectomized rats [38] 
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myrtilloides  Michx. 
Eucom miaulmoides Oliv Eucommiaceae Bark Prevention of bone loss induced by 
estrogen deﬁciency 
Rat pituitary cells/ 
five ovariectomy 
(OVX) subgroups 
[39,40,41] 
Butea monosperma 
 (Lamk.) Kuntze 
Fabaceae Stem bark Prevention of bone loss induced by 
ovariectomy through stimulating bone 
formation 
Ovariectomized rats [42] 
Phaseolus vulgaris L. Fabaceae Seed Prevention of osteopenia induced by 
estrogen deﬁciency without affecting the 
uterine mass 
Ovariectomized rats [43] 
Allium cepa L. Liliaceae Bulb Decrease of the ovariectomy-induced 
bone resorption 
Ovariectomized rats [44] 
Allium sativum L. Liliaceae Bulb Prevention of bone loss, reverse of the 
low BMD and decrease of tensile 
strength caused by ovariectomy 
Ovariectomized rats [45] 
Anemarrhena 
asphodeloides Bunge 
Liliaceae Rhizome Prevention of bone loss induced by 
ovariectomy through promotion of bone 
formation but not inhibition of bone 
resorption 
Ovariectomized rats [46] 
Abelmoschus manihot 
 (L.) Medicus 
Malvaceae Leaf Reduction of bone loss in conditions of 
estrogen deﬁciency 
 [47] 
Tinospora cordifolia 
Vanda  
Menispermaceae Stem Prevention of bone loss induced by 
ovariectomy 
ovariectomized rats [48] 
Anoectochilus 
formosanus Hayata 
Orchidaceae Whole 
plant 
Suppression of the bone loss caused by 
estrogen deﬁciency 
 [49] 
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Cistanche 
salsa  (C.A.Mey) G. 
Beck 
Orobanchaceae Stem Prevention of bone loss induced by 
ovariectomy 
ovariectomized 
mice 
[50] 
Rubus coreanus Miq. Rosaceae Fruit Prevention of bone loss caused by 
estrogen deﬁciency by dual regulation of 
the enhancement of osteoblast function 
and induction 
 [51,52] 
Rehmannia 
glutinosa  Libosch 
Scrophulariaceae Root Increase of the cortical bone thickness in 
ovariectomy-induced osteoporotic 
rats 
ovariectomized 
rats 
[53] 
Withania somnifera 
(L.)Dunal 
Solanaceae Root Inhibition of bone loss in 
ovariectomized rats 
ovariectomized 
rats 
[54] 
Taxus yunnanensis Cheng Taxaceae Seed, 
bark 
Increase of bone mineral content and 
bone mineral density in ovariectomized 
rats 
ovariectomized 
rats 
[55] 
Ulmus wallichiana 
Planch. 
Ulmaceae Bark Mitigation of ovariectomy-induced 
osteoporosis in rats, stimulation of 
osteoblast function and inhibition of 
osteoclast diﬀerentiation 
ovariectomized 
rats 
[56,57] 
Cissus quadrangularis L. Vitaceae Aerial 
parts, 
root 
Prevention of bone loss in 
ovariectomized rats. 
ovariectomized 
rats 
[58] 
Curcuma comosa Roxb. Zingiberaceae Rhizome Prevention of bone loss induced by 
estrogen deﬁciency 
 [59] 
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Table 2  Traditional formulations for the treatment of kidney deficiency and osteoporosis 
Formulation  Syndrome Model Composition Pharmacological effect Reference 
Er-Zhi Wan Deficiency of 
kidney-yin 
10% Monosodium glutamate 
(MSG), 2, 4, 6, 8, 10 d, 4 
g/kg·d-1, neonatal rat, Male 
Eclipta prostrate, Ligustrum 
lucidum 
Prevention of osteoporosis induced 
by the deficiency of kidney-yin 
through inhibition of the 
hypothalamic nerve cells apoptosis 
and up-regulation of serum 
estradiol. 
[60] 
Jiawei Yanghe 
decoction 
Deficiency of 
kidney-yang 
Postmenopausal women Colla Plastri Testudinis, Colla 
Cornus Cervi, Rhizoma 
Rehmannina Praeparatae, Cortex 
Cinnamomi, Herba Ephedrae, 
Rhizoma Zingiberis, Glycyrrhiiza 
uraleusis Fisch, Salvia 
miltiorrhiza Bunge 
Prevention and treatment of 
osteoporosis through inhibition of 
osteoclasts formation and 
resorption, promotion of bone 
formation, and improvement of 
bone mineral density.  
[61] 
Qiangji Jianli Yin Deficiency of 
kidney-yang 
Hydrocortisone, 25 
mg· kg-1· d-1, Sprague–Dawley 
rat, Male 
Astragalus membranaceus, 
Codonopsis pilosula, 
Atractylodes macrocephala, 
Angelica sinensis, Cimicifuga 
heracleifolia, Glycyrrhiza 
uralensis 
Prevention and treatment of 
Deficiency of kidney-yang in rats is 
related with the regulation of the 
hypothalamic-pituitary-gonad Axis.  
[23] 
You-Gui Wan Deficiency of 
kidney-yang 
Hydrocortisone, 25 mg/kg,  
Wistar rat, Male 
Dioscorea opposite, Cuscuta 
australis, Eucommia ulmoides, 
Rehmannia glutinosa, Lycium 
barbarum, 
Improvement of the deficiency of 
kidney-yang through up-regulation 
of testosterone content. 
[24] 
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Jiawei Zuogui Wan  Deficiency of 
kidney-yin 
Clinical treatment Rehmannia glutinosa, Lycium 
barbarum, Dioscorea opposite, 
Cornus officinalis, Cyathula 
officinalis, Cuscuta australis, 
Colla cornus cervi, Poria cocos 
Astragalus membranaceus, 
Atractylodes macrocephala, 
Epimedium brevicornu  
Improvement of osteoporosis 
symptoms and increase the bone 
BMD. 
[62] 
Liuwei Dihuang 
decoction 
Kidney 
deficiency 
Clinical treatment Rehmannia glutinosa, Dioscorea 
opposite, Cornus officinalis, 
Poria cocos, Alisma orientalis, 
Paeonia suffruticosa 
Prevention and treatment of 
osteoporosis is related with 
stimulate bone formation. 
[63] 
Rongjin Tablets Kidney 
deficiency and 
blood stasis type 
Clinical treatment Glycyrrhiza uralensis, 
Achyranthes bidentata, Tribulus 
terrestris, Poria cocos 
Significant improvement of the 
kidney deficiency and blood stasis 
type of primary osteoporosis.  
[64] 
Invigorating 
kidney pill 
 Oestrus stage mice, female Rehmannia glutinosa, Dioscorea 
opposite, Cornus officinalis, 
Lycium barbarum, Rubus chingii, 
Morinda officinalis, Cuscuta 
australis, Eucommia ulmoides, 
Achyranthes bidentata, 
Astragalus membranaceus, Poria 
cocos  
Increase of FSH, LH and E2, esp., 
wet weight of ovary. Integration of 
the reproduction and endocrine 
system with different levels of 
hypothalamus, pituitary and sexual 
gland. 
[65] 
 
 
 
